Voxilaprevir + Gemfibrozil = Unknown or no reaction

Effect on Concentration

Voxilaprevir
No change
Applies within class?
No
Gemfibrozil
Unknown
Applies within class?
No

Pharmacologic Effects

Voxilaprevir
Effect
N/A
Applies within class?
No
Gemfibrozil
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 22-Nov-2022

Summary

The authors concluded that potent inhibition of CYP 2C8 had no effect on GS-9857 exposure, and that GS-9857 may be administered with inhibitors of CYP 2C8 could be undertaken without dose modification.

Sources

Voxilaprevir vs 5 drugs ^

Study Design

This was an open label, single and multiple dose four cohort study in 98 healthy volunteers. Participants were administered a single dose of GS-9857 100 mg alone or in combination with inhibitors or inducers of drug transporters or CYP isoenzymes. These drugs included rifampin 600 mg x 1 dose fasted, or rifampin 600 mg daily for seven days fed. Geometric means ratios and 90% Confidence Intervals for GS-9857 were estimated and compared to pre-specified lack of PK alteration boundaries 70% - 143%. Safety was assessed by routine laboratory and clinical monitoring. Five subjects discontinued the study drug during the study period.

Study Results

The study data were not given, but the authors concluded that GS-9857 concentrations were not affected by coadministration with gemfibrozil.

Study Conclusions

References

Kirby BJ, J Taylor, Stamm LM, Q Song, Y Li, A Mathias. Evaluation of pan genotypic hcv ns3/4a protease inhibitor gs-9857 as the object of transporter and cytochrome p450 mediated drug-drug interactions. 17th International Workshop On Clinical Pharmacology Of Hiv And Hepatitis Therapy. Washington, DC, USA. ; 2016.